Biomarkers /
PRKCZ
Overview
PRKCZ is altered in 0.47% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, bladder urothelial carcinoma, and conventional glioblastoma multiforme having the greatest prevalence of alterations [3].
The most common alterations in PRKCZ are PRKCZ Amplification (0.14%), PRKCZ Loss (0.09%), PRKCZ Fusion (0.02%), PRKCZ P177L (0.04%), and PRKCZ A142V (0.04%) [3].
Clinical Trials
Significance of PRKCZ in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.